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Abstract
Yin-Yang 1 (YY1) is an essential multifunctional zinc-finger protein. It has been shown over the past two decades to be a
critical regulator of a vast array of biological processes, including development, cell proliferation and differentiation, DNA
repair, and apoptosis. YY1 exerts its functions primarily as a transcription factor that can activate or repress gene expression,
dependent on its spatial and temporal context. YY1 regulates a large number of genes involved in cell cycle transitions,
many of which are oncogenes and tumor-suppressor genes. YY1 itself has been classified as an oncogene and was found to
be upregulated in many cancer types. Unfortunately, our knowledge of what regulates YY1 is very minimal. Although YY1
has been shown to be a phosphoprotein, no kinase has ever been identified for the phosphorylation of YY1. Polo-like kinase
1 (Plk1) has emerged in the past few years as a major cell cycle regulator, particularly for cell division. Plk1 has been shown
to play important roles in the G/M transition into mitosis and for the proper execution of cytokinesis, processes that YY1 has
been shown to regulate also. Here, we present evidence that Plk1 directly phosphorylates YY1 in vitro and in vivo at
threonine 39 in the activation domain. We show that this phosphorylation is cell cycle regulated and peaks at G2/M. This is
the first report identifying a kinase for which YY1 is a substrate.
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Introduction
YY1 is a ubiquitously expressed multifunctional transcription
factor that has been shown to be involved in the regulation of a
large number of genes that are critical for basic biological
processes of cell growth, development, differentiation, cell cycle
and even programmed cell death (apoptosis) (reviewed in [1,2]).
YY1 is an essential protein; its complete ablation was shown to
cause lethality in mice at day seven of embryogenesis and
disruption of one allele causes severe developmental defects [3].
The structural and functional domains of the YY1 protein have
been well characterized. YY1 is a sequence-specific DNA binding
C2H2 zinc finger protein that contains both a transactivation
domain and a repression domain [4,5]. The role of YY1 in cellular
proliferation has been proposed since its discovery [6]. This was
further supported by identification of several cell cycle regulators
that are modulated by YY1, like c-Myc [7,8,9], RB [10,11], p53
[12,13,14,15], and many others. In addition, knockdown of YY1
was shown to reducecell proliferationand cause an accumulationof
multinucleated cells with a variety of nuclear abnormalities [16].
Thisis possiblydueto a role forYY1in the regulationof cytokinesis.
This role could be direct or indirect. In the analysis of the effects of
YY1 knockdown on gene expression, a cluster of genes normally
upregulated at G2/M was found to be down-regulated [16].
The involvement of YY1 in cell proliferation and regulation of
oncogenes and tumor-suppressor genes has led several groups to
investigate the role of YY1 in tumor development (reviewed in
[2,17,18,19]. For example, elevated YY1 levels were detected in
many tumor types including prostate cancer [20,21], ovarian
cancer [19], colon cancer [22], breast cancer [22], cervical cancer
[23], osteosarcoma [24], acute myeloid leukemia [25,26],
Hodgkin’s lymphoma [19,27], non-Hodgkin’s lymphoma [28],
and follicular lymphoma [29]. In addition, higher YY1 transcript
and protein levels were associated with malignant transformation
in cervical cancer, in the presence of a Human Papilloma Virus
(HPV) infection [30].
Although a substantial amount of information has been
compiled over the past decade about target genes regulated by
YY1, much less evidence has been gathered to provide a model for
its mode of action and, more importantly, its regulation. The
expression and protein levels of YY1 remain constant across the
different phases of the cell cycle [31,32,33]. This leads to the
possibility that YY1 is regulated by post-translational modification,
phosphorylation in particular, to play specific roles at specific time
points in the cell cycle. We have previously reported that
phosphorylation of YY1 in the DNA binding domain during
mitosis abolishes its DNA binding activity [31]. Also, several large
scale proteomics studies have mapped phosphorylation sites on
YY1, including serines 118, 184, 247, threonines 348 and 378
[34,35,36,37] but no particular kinase has ever been identified.
Polo-like kinase one (Plk1) is a serine/threonine kinase, initially
identified in Drosophila as Polo, and shown to play pivotal roles in
proper spindle pole formation [38]. In mammalian cells, Plk1 is a
critical regulator of several important cell cycle events [39].
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accurate and timely execution of mitosis and cytokinesis
[40,41,42]. Plk1 has received significant interest in the past few
years due to its role in cell proliferation and its upregulation in
many types of cancer, leading to its targeting in cancer therapies
[43,44,45,46,47,48]. Clinical trials are already underway [43].
Many groups have focused on elucidating the various roles played
by Plk1 in cell division by identifying an array of substrates,
including enzymes, spindle checkpoint proteins, and structural
proteins [49,50,51,52,53,54,55,56,57,58,59,60]. Recently, a study
has found the first direct link between Plk1 and transcriptional
regulation at G2/M, by identifying Forkhead Box M1 (FoxM1)
transcription factor as a physiological substrate for Plk1 [61].
FoxM1 is an important activator of a cluster of genes needed for
progression into mitosis. Plk1 phosphorylation of FoxM1 was
shown to provide a positive feedback loop for mitotic entry [61].
Here, we report the first identification of a kinase that
phosphorylates the transcription factor YY1. We identify a novel
phosphorylation site in the activation domain of YY1 and show
that this phosphorylation is cell cycle regulated, peaking at G2/M.
We show that Plk1 is the kinase that phosphorylates YY1 at this
site, revealing an additional link between Plk1 and the transcrip-
tional machinery at the entry of mitosis.
Results
YY1 is a direct substrate for Plk1 in vitro
Due to the critical role that the transcription factor YY1 plays in
the life of mammalian cells, and its link to cancer, there is an
urgent need for a better understanding of its regulation. Although
YY1 has been proposed [62] and shown to be a phosphoprotein
[31], there is no evidence in the scientific literature of a
phosphorylation signaling pathway which directly regulates YY1.
More specifically, YY1 has never been shown to be the direct
substrate of any specific kinase.
To explore these signaling pathways and screen various
upstream kinases, we developed a novel method for the
purification of bacterially expressed YY1, without the need for
any tagging system. The N-terminal domain of YY1 contains a
stretch of 11 histidine residues that can potentially fulfill the role of
a His-tag. Initial attempts to purify YY1, using this natural His tag,
under native conditions, were not successful. This was most likely
due to shielding of the histidine stretch in the three dimensional
folding of the protein. However, when the purification was
performed under denaturing conditions, high yields of pure YY1
were readily produced (Fig. 1A). After optimizing renaturation
conditions, as described in the Material and Methods section, we
were able to obtain pure YY1 protein (Fig. 1 B). YY1 is a
transcription factor, and its DNA binding activity has been well
characterized. Therefore, we tested its proper functional folding
using an in vitro DNA binding assay. Renatured YY1 was able to
bind its DNA consensus site found in the coding region of Histone
H3.2, in an electrophoretic-mobility shift assay (EMSA), as
previously described (Fig. 1C) [63]. In addition, to provide
evidence that most of the renatured YY1 was functional, we used
comparable amounts of purified YY1 to those found in HeLa
whole cell extracts. As shown in Figure 1C, equal amounts of the
YY1 protein from the two sources generated comparable shifts in
the EMSA assay. Purified YY1 was also able to bind several
previously identified consensus binding sites from different
biological contexts [6,64] in EMSA assays (data not shown).
To search for kinases that could phosphorylate YY1, we used
the GPS 2.0 (Group-based Prediction System) software (http://
gps.biocuckoo.org) [65]. Several kinases were predicted to
phosphorylate YY1 at distinct residues. Since we were particularly
interested in the role and regulation of YY1 in the context of cell
proliferation, we narrowed our search to the kinases that are
involved in cell cycle regulation. The main kinase of this category
which had several consensus sites in YY1 was Plk1.
To test if YY1 is indeed a good substrate for Plk1, we performed
a radioactive in vitro kinase assay using purified YY1 and Plk1,
expressed and purified from insect cells (SignalChem). As shown in
Figure 1D, Plk1 was able to phosphorylate YY1 in vitro. YY1 alone
did not show any kinase or autophosphorylation activity (Fig. 1D),
as previously reported [1,31].
Plk1 phosphorylates YY1 at threonine 39 in the N-
terminal activation domain
Several sites on YY1 were predicted to be potential phosphor-
ylation sites for Plk1, and resembled previously reported Plk1
phosphorylation sites on other proteins [59,66]. To map the exact
residue(s) that Plk1 phosphorylates on YY1, we followed a two-step
approach.
First, we used a panel of YY1 deletion mutants, which had a
Glutathione-S-Transferase (GST) tag. GST-YY1, full length or
various deletion mutants, was overexpressed in bacterial cells, and
then bacterial lysates were used in a radioactive in vitro kinase assay
with purified Plk1. As shown in Figure 2A, Plk1 was able to
efficiently phosphorylate full-length YY1. However, phosphoryla-
tion was abolished with the deletion of the first 62 amino acid
residues. Phosphorylation was also abolished in YY1 mutants
having additional deletions from the N-terminal side (2–119, 2–
197, and 2–273). Deletion of the entire C-terminal domain (153–
414), had no effect on the phosphorylation of YY1; neither did
deletions of residues 92–153, 154–199, 262–299, 266–331, and
399–414. A diagram displaying these results is presented in
Figure 2B. This evidence indicates that the first 62 amino acid
residues of YY1 are crucial for the phosphorylation by Plk1.
Then, we analyzed the amino acid composition of the N-
terminal residues of YY1. Eight serine and threonine residues were
found in this sequence. However, only one threonine, at position
39, resembles a possible Plk1 consensus site (Fig. 3A) [59]. To test
if threonine 39 is the Plk1 phosphorylation site, we mutated this
residue to alanine, generating a GST-YY1 (T39A) mutant. When
tested in a radioactive in vitro kinase assay with Plk1, the GST-YY1
(T39A) mutant displayed significantly reduced phosphorylation
relative to the wild type (Fig. 3B). Next, we analyzed the
conservation of threonine 39 residue of YY1 among different
species. We found that it is very well conserved in human, mice,
rat, chicken, frog, zebrafish, and cattle (Fig. 3C). In addition, the
amino acid residues surrounding this site, and contributing to the
formation of a consensus sequence, were also conserved; especially
a negatively charged glutamic acid residue at position 22 and an
aliphatic residue (valine) at position +1, relative to threonine 39
[59].
Anti-phospho-T39 antibody specifically recognizes
phosphorylation of YY1 by Plk1
To characterize the phosphorylation of YY1 at threonine 39
and study its occurrence in cells, a phospho-specific antibody was
raised against a synthetic peptide encompassing YY1 residues 33–
44, and carrying a phosphorylation at T39 residue. The polyclonal
antibody (anti-pT39) was generated in rabbit, and purified on
phosphospecific affinity columns. To test the specificity of anti-
pT39 in recognizing the phosphorylation of YY1 by Plk1, we
performed a cold in vitro kinase assay using purified Plk1 and YY1.
The kinase reactions were separated on an SDS-PAGE gel and
Phosphorylation of YY1 by Plk1
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probed with anti-pT39 antibody, one band was detected in the
lane where YY1 was incubated with Plk1 but not in the YY1-only
lane (Fig. 4A). Re-probing the blot with YY1 specific antibody
confirmed the band as YY1, and showed an equal band in the
YY1-only lane. To further test the specificity of the antibody for
threonine 39, a second cold kinase assay was performed using
GST-YY1 wild type (WT) or mutant (T39A), as substrates. When
the reactions were analyzed with Western blotting, and probed
with anti-pT39, a band was detected only for GST-YY1 (WT)
incubated with Plk1 (Fig. 4B).
Phosphorylation of YY1 at T39 peaks at G2/M transition
The next question is whether this modification occurs on YY1 in
vivo and if it is cell cycle regulated. For this purpose we
synchronized HeLa cells stably transfected with Flag-YY1 [31],
using double-thymidine block, as described in the methods section.
After the second block, cells were released into fresh medium and
samples were collected either for cell cycle analysis using
propidium iodide staining followed by Fluorescence Activated
Cell Sorting (FACS) analysis, or for whole cell extract (WCE)
preparation. Figure 5A shows the cell cycle distribution of cells as
they progress from the block. An asynchronous population of
HeLa-Flag-YY1 was also analyzed by FACS, as a control. Cells
blocked with double-thymidine show early S-phase content of
DNA. After release, cells progressed into S-phase, at 2 hours and
4 hours. At 6 hours, cells appear to have G2 level of DNA content,
and at 8 hours, they appear to be at late G2 and moving through
G2/M into mitosis. At 10 hours, most cells had exited mitosis and
entered G1. Twelve hours after release, all cells were in G1 of the
new cell cycle (Fig. 5A). An analysis of the synchronized cell
extracts on a Western blot showed that the levels of Plk1 and
Cyclin B1 increased as cells progress into S-phase and G2, and
peaked at G2/M of the cell cycle. Both Plk1 and Cyclin B1 levels
Figure 1. Plk1 phosphorylates YY1 in vitro. (A) Coomassie blue staining of SDS-PAGE gel showing the purification of bacterially expressed non-
tagged YY1 under denaturing conditions. An arrow indicates the position of overexpressed YY1. Lysates: sample from total bacterial lysates; Depleted
lysates: sample from bacterial lysates after passing through the Ni-NTA column. E1, 2, and 3 are samples from elutions at pH 5.9; E4, 5, and 6 are
samples from elutions at pH 4.5; the last lane shows a sample of the Ni-NTA beads after the last elution step. (B) Coomassie blue staining (left panel)
and Western blot analysis (right panel) of purified YY1 after renaturation, and separation by SDS-PAGE. In the Western blot, YY1 was probed with anti-
YY1 (H-10) antibody. (C) EMSA testing the DNA binding activity of purified and renatured YY1 side by side with HeLa whole cell extract. A 22 bp
oligonucleotide encompassing the YY1 binding site in histone H3.2 coding region was used as the radioactively labeled probe. The Western blot
shows equal amounts of purified YY1 and YY1 protein in HeLa WCEs. (D) Coomassie blue staining and phosphorimager exposure of SDS-PAGE gel
after radioactive in vitro kinase assay, using purified Plk1 and YY1. The gel shows three reactions: Plk1 only, YY1 only, and Plk1 plus YY1; as indicated.
doi:10.1371/journal.pone.0015928.g001
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Cyclin B1 levels started at 10 hours, while Plk1 levels remained
high until the 12 hour time point. Both endogenous YY1 and
Flag-YY1 protein levels remain constant (Fig. 5B). These results
are consistent with previous reports by several groups [67,68,69].
To analyze the threonine 39 phosphorylation on YY1, Flag-YY1
was immunoprecipitated from WCEs prepared from each time
point, loaded on an SDS-PAGE gel, transferred to a nitrocellulose
membrane, and probed with anti-pT39 and anti-YY1 antibodies.
Although the level of immunoprecipitated YY1 was equal in each
time point, detection of T39 phosphorylation was mainly at the
8 hour time point (Fig. 5B), in correlation with the high peak of
Plk1 protein levels. This also correlates with previous reports of the
timing of the high peak of Plk1 kinase activity [68,70].
Interestingly, the levels of YY1 T39 phosphorylation decreases
sharply as cells progress into mitosis, which shows that this
phosphorylation has a very specific temporal occurrence at G2/M.
To reproduce this result and further analyze the timing of the T39
phosphorylation, the same experiment was repeated, but cells were
collected at time points 5, 6, 7, 8, 9, and 10 hours (Fig. 6). Similar
results were obtained for Plk1 and YY1 levels. Cyclin B1 levels
were shown to decrease sharply between 8–9 hours, as expected
for a well synchronized population of cells, and it marks the
transition through prophase, metaphase and into anaphase [69].
Following this same time line, T39 phosphorylation of YY1 also
decreased sharply between 8 to 9 hours (Fig. 6A). This is
particularly interesting, because the levels of Plk1 remain high at
these time points. However, it has been reported previously that
Plk1 changes its cellular localization and substrate specificity at
later stages of mitosis, playing specific roles for the proper
execution of cytokinesis [40,66]. To test if Plk1 at the 9 and
10 hour-time points is active and can phosphorylate YY1, we
performed an in vitro kinase assay using the same timed cell extracts
in panel A with GST-YY1 as a substrate. As shown in Figure 6B,
GST-YY1 was efficiently phosphorylated by the 9 hour-time point
extracts, and to a lesser extent by the 10 hour-time point extracts.
Next, we wanted to provide more in vivo evidence that YY1 is a
substrate for Plk1, specifically at the G2/M transition of the cell
cycle. For this purpose we prepared WCEs from HeLa cells,
asynchronously growing or double-thymidine blocked and re-
leased for 8 hours (T/T 8 h). Synchrony at G2/M transition was
verified using FACS analysis (data not shown). In addition,
Western blot analysis showed higher levels of Plk1 and Cyclin B1
in T/T8 h extracts, relative to asynchronous extracts (Fig. 7A,
right panel). Then, asynchronous or T/T8 h extracts were used in
a cold in vitro kinase assay with GST-YY1, in the absence or
Figure 2. Plk1 phosphorylates YY1 in the N-terminal activation domain in vitro. (A) Coomassie blue staining (left) and phosphorimager
exposure (right) of SDS-PAGE gel analysis of the radioactive in vitro kinase assay reactions using purified Plk1 and a panel of GST-tagged YY1
deletion mutants. The specific YY1 deletions are indicated above the lanes. Equal amounts of purified Plk1 were added to all reactions. (B) Diagram of
the deletion mutants of YY1 used in the kinase assay in (A). Evidence of phosphorylation shown in (A) is indicated by the (+) sign, whereas the
absence of evidence of phosphorylation is indicated by a (--) sign. The region identified as the site for phosphorylation by Plk1 is indicated
(amino acid residues 2–62).
doi:10.1371/journal.pone.0015928.g002
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inhibitor. The kinase reactions were analyzed by Western blot,
using anti-pT39 and anti-YY1 antibodies. Figure 7A shows that
incubation of GST-YY1 with the WCEs from T/T8 h results in
much higher T39 phosphorylation than the WCEs from the
asynchronous population, correlating with the high level of Plk1
activity. Moreover, the addition of Plk1 inhibitor (Cyclapolin 9)
[71] greatly reduced GST-YY1 T39 phosphorylation; indicating
that the corresponding kinase activity in T/T8 h extracts was
indeed due to Plk1. Next, we synchronized HeLa-Flag-YY1 cells
with double-thymidine, released, and harvested at 8 hours after
release, with or without the addition of Cyclapolin 9 at 4 hours
after release. Two different concentrations of Cyclapolin 9 were
added, 5 and 10 mM. WCEs were prepared, and Flag-YY1 was
immunoprecipitated and analyzed on a Western blot with anti-
pT39 and anti-YY1 antibodies. The levels of immunoprecipitated
Flag-YY1 were shown to be equal; however, the level of T39
phosphorylation sharply decreased upon addition of Plk1 inhibitor
(Fig. 7B). Flag-YY1 was also immunoprecipitated from WCE of
cells collected at 2 hours after release as a negative control for the
phosphorylation (T/T 2 h). To further prove that YY1 is an in vivo
substrate of Plk1, we performed co-immunoprecipitation experi-
ments using WCEs from HeLa cells which were double-thymidine
blocked and released for 8 hours. We observed that Plk1 co-
immunoprecipitated with endogenous YY1, using a C-terminal
YY1 specific antibody (Fig. 7C). This is direct evidence for an in
Figure 3. Plk1 phosphorylates YY1 at threonine 39 in vitro. (A) Diagram displaying the different domains of the YY1 protein. Amino acid
residues 2–62 are shown; serine and threonine residues in amino acids 2–62 are indicated by arrows. The predicted phosphorylation site at threonine
39 is indicated with a star. (B) Coomassie blue staining and phosphorimager exposure of the SDS-PAGE gel analysis of the radioactive in vitro kinase
assay reactions. Kinase reactions include Plk1 only (no substrate lane), Plk1 with GST-YY1 wild type (WT) or mutant (T39A). (C) Amino acid sequence
alignment of the N-terminal domain of the YY1 protein from different species, as indicated.
doi:10.1371/journal.pone.0015928.g003
Figure 4. Anti-p-T39 antibody specifically recognizes YY1 phosphorylation at threonine 39. (A) Western blot analysis of the cold in vitro
kinase assay reactions using purified Plk1 and purified YY1, after SDS-PAGE. The blot was probed with anti-YY1, anti-Plk1 and anti-pT39 antibodies.
(B) Western blot analysis of the cold in vitro kinase assay reactions after SDS-PAGE, using purified Plk1 and purified GST-YY1 wild type (WT) or mutant
(T39A). The blot was probed with anti-YY1, anti-Plk1 and anti-pT39 antibodies.
doi:10.1371/journal.pone.0015928.g004
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transition of the cell cycle.
Discussion
Strict control of entry into mitosis is essential for the proper
execution of cell division and the accurate distribution of the
genetic material to the two daughter cells. This control is ordered
by an elaborate network of phosphorylation signaling pathways,
and positive and negative feedback loops. Disruption of these
pathways can lead to fatal diseases in humans, such as cancer. A
better understanding of these pathways and their regulation can
lead to enhanced therapies.
The transcription factor YY1 has been shown to be one of the
major regulators in development and cell proliferation. An
abundance of evidence in the literature supports the critical roles
of YY1 in the transitions through the different phases of the cell
cycle [1,2,63]. However, the mechanisms for the modulation of
these roles are not clear. Expression of the yy1 gene and YY1
protein levels do not fluctuate throughout the cell cycle. Most
hypotheses proposed for the different roles and temporal
regulation of YY1 have pointed to external elements, like
interactions with proteins that in turn are cell cycle regulated.
Our research has focused on posttranslational modifications which
can occur on YY1 in a cell cycle dependent manner. For this
purpose, we analyzed the amino acid sequence of YY1 and
searched for consensus sites for phosphorylation by different cell
cycle kinases. One of the kinases that showed high probability for
phosphorylation of YY1 was Plk1. This prediction seemed
reasonable due to the functional overlap between YY1 and Plk1
in the proper progression of mitosis and cytokinesis [16].
To test this prediction, we performed a series of radioactive in
vitro kinase assays. We showed that YY1 is a good substrate for
Plk1 and we mapped the phosphorylation site to theonine 39 of
Figure 5. Threonine 39 phosphorylation on YY1 peaks at G2/M transition. Stable HeLa-Flag-YY1 cells were synchronized by double-
thymidine block and then released. (A) Analysis of the cell-cycle progression of HeLa cells released after double-thymidine block using fluorescence-
activatedcellsorting.CellswerestainedwithpropidiumiodideandanalyzedbasedontheirDNAcontent.Anasynchronouspopulationofcellswas used
as a control. (B) Whole cell extracts were prepared from HeLa-Flag-YY1 cells collected at the indicated times after release from double-thymidine block.
Total WCE were analyzed on a Western blot after SDS-PAGE separation, and probed with anti-Plk1, anti-Cyclin B1, and anti-YY1 antibodies. Flag-YY1 was
immunoprecipitated from the extracts of each time point, and then analyzed on a Western blot using anti-pT39 and anti-YY1 antibodies.
doi:10.1371/journal.pone.0015928.g005
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synchronized by double-thymidine block and then released. Cells were collected for WCE preparation at the indicated time points. (A) Western blot
analysis of HeLa WCEs and immunoprecipitated Flag-YY1 at the indicated time points. WCEs were probed with anti-Plk1, anti-Cyclin B1, and anti-YY1
antibodies. Immunoprecipitated Flag-YY1 was probed with anti-pT39 and anti-YY1 antibodies. (B) In vitro kinase assay using the same WCEs tested in
(A) at the indicated time points with GST-YY1 attached to beads, in the presence of phosphatase inhibitors. Reactions were separated on SDS-PAGE,
transferred to nitrocellulose membrane, and probed with anti-pT39, then anti-YY1 antibody.
doi:10.1371/journal.pone.0015928.g006
Figure 7. Plk1 phosphorylates YY1 at threonine 39 in vivo. (A) Western blot analysis of cold in vitro kinase assay reactions using HeLa whole
cell extracts (WCE) as the source for kinase activity and bacterially expressed GST-YY1 bound to glutathione beads, as substrate. WCEs were prepared
from HeLa cells, asynchronously growing or double-thymidine blocked and released for eight hours (T/T 8 h). Plk1 inhibitor, Cyclapolin 9, was added
to the kinase reactions of T/T 8 h extracts at the indicated concentrations. Reactions were separated on SDS-PAGE, transferred to nitrocellulose
membrane, and probed with anti-pT39, then anti-YY1 antibody. WCEs were also analyzed on a separate Western blot (right panel), using anti-Plk1
and anti-Cyclin B1 antibodies. Anti-GAPDH was used as a loading control. (B) Flag-YY1 was immunoprecipitated from HeLa-Flag-YY1 cells,
synchronized by double-thymidine block and released for eight hours. Cyclapolin 9 (or DMSO, for the negative control for the inhibitor) was added to
the cells four hours prior to cell collection. Flag-YY1 was also immunoprecipitated from cell extracts collected two hours after release as a negative
control. The resulting Western blot was probed with anti-pT39 and anti-YY1 antibodies. (C) Co-immunoprecipitation of Plk1 with YY1 from WCEs
prepared from HeLa cells released for eight hours after double thymidine block. YY1 was immunoprecipitated using an antibody specific for the last
20 amino acids of the YY1 (C-20). IgG was used as a control for the specificity of the immunoprecipitation. The Western blot was probed with anti-
Plk1 and then anti-YY1 antibodies.
doi:10.1371/journal.pone.0015928.g007
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recognize phosphorylated threonine 39 (anti-pT39). This antibody
showed high specificity for phospho-T39 on YY1, when
phosphorylated by Plk1 in vitro.
When whole cell extracts from asynchronous HeLa cells were
tested on Western blot, the antibody produced several cross-
reacting bands (data not shown). Therefore, we tested this
antibody on immunoprecipitated Flag-tagged YY1, from different
time points of the cell cycle. Anti-pT39 recognized phosphorylated
Flag-YY1 only in late G2, and mainly at G2/M transition,
although the levels of immunoprecipitated YY1 were identical at
all time points (Fig. 5). The inability of the antibody to recognize
phosphorylation on YY1 in asynchronous WCE is likely due to the
low stoichiometry of this phosphorylation, since it occurs during a
very short time interval of the cell cycle. Also, it possibly occurs
only on a limited subpopulation of YY1 protein.
Many Plk1 substrates have been shown to be primed for
phosphorylation by Plk1 by other kinases [58,66]. Since Plk1
strongly phosphorylated bacterially expressed YY1 in vitro, it does
not appear to require a priming phosphorylation. However, this
does not exclude the possibility that priming of YY1 on a different
site in vivo could play an important role in modulating this
phosphorylation.
An interesting finding in this study was the rapid dephosphor-
ylation of threonine 39, as cells progress into mitosis. In contrast to
this rapid dephosphorylation, the levels of Plk1 remain high well
beyond the time of the loss of T39 phosphorylation, as shown in
our assays. Plk1 activity has been known to persist throughout
mitosis and cytokinesis [41,67,68,70]. This is also supported by our
in vitro kinase assay, in which Plk1 in cell extracts from the 9 hour
time point can efficiently phosphorylate YY1 in vitro. Therefore, it
is possible that a strong phosphatase activity somehow overcomes
the phosphorylation of YY1 by Plk1, and that Plk1 only
phosphorylates YY1 at the entry into mitosis in vivo. These
possibilities are not mutually exclusive, but rather more probably
coordinated. The cellular distribution and changes of localization
of Plk1 at later stages of mitosis have been shown to play a
significant role in its substrate recognition [40,41,58,66]. This
indicates that Plk1 phosphorylation of YY1 has a very precise role
at this point of the cell cycle, and it could be an indirect
mechanism through which Plk1 regulates the expression of
proteins needed later in cytokinesis. Evidence that YY1 is a
physiological substrate for Plk1 is strengthened by the physical
interaction between YY1 and Plk1 shown by co-immunoprecip-
itation. Also, selective inhibition of Plk1 phosphorylation of YY1
by Cyclapolin 9 [71] is consistent with the conclusion that Plk1 is
the kinase responsible for T39 phosphorylation.
The timing of threonine 39 phosphorylation functionally
overlaps with YY1 regulation of genes activated at G2/M.
Overexpression of Flag-YY1, where threonine 39 is mutated to
alanine (non-phosphorylatable) or to aspartic acid (phosphomi-
micking), did not produce significant phenotypic effects in HeLa
cells (data not shown). This could be due to the abundance of
endogenous wild type YY1 or the need for other modifications on
YY1 to produce phenotypic effects. Future studies will help reveal
the exact function of this modification.
In summary, we reveal in this report the first identification of a
kinase which phosphorylates YY1. This phosphorylation occurs in
the activation domain of YY1 and is cell cycle regulated. We show,
in vitro and in vivo, that YY1 is a good substrate for Plk1 and
implicate YY1 in the cascade of signaling events that take place at
G2/M transition. A better understanding of all the elements
involved in the entry into mitosis is of critical importance in
enhancing targeted cancer therapies.
Materials and Methods
Cell Culture
HeLa S3 and HeLa-Flag-YY1 [31] cells were grown at 37uCi n
5% CO2 in Dulbecco’s Modified Eagle Medium (DMEM) (Cellgro,
Herndon, VA) supplemented with 10% Fetal Bovine Serum (FBS)
(FBS; Mediatech, Herndon, VA), 1% Non-Essential amino acids
(Sigma, St. Louis, MO) and 1% Penicillin-Streptomycin (Media-
tech). HeLa-Flag-YY1 cells are stably transfected with pCS2(+)-
Flag-YY1. Double-thymidine synchronization and establishment of
HeLa-Flag-YY1 stable cell line was described previously [31].
Whole Cell Extract (WCE) preparation, Immunoprecipitation
(IP), Western blotting and Electrophoretic-Mobility Shift Assays
(EMSA) were performed as previously described [31,63]. Antibody
used for IP was anti-YY1(C-20); antibodies used for Western
blotting were anti-YY1 (H-10), anti-Plk1, anti-Cyclin B1, anti-
GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA). The rabbit
polyclonal anti-pT39 was generated by New England Peptide
using a synthesized phospho-peptide corresponding to amino acids
33–44 of YY1 (Ac-VETIET(pT)VVGEEC-amide).
Plasmid construction
pGEX-2T-YY1. For the construction of GST-tagged YY1
bacterialexpressionplasmid,anNcoI/EcoI fragmentencompassing
the open reading frame of human YY1 was moved from pCMV-
HA-YY1 (a gift from Dr. Bernhard Lu ¨scher, Aachen University,
Germany)[5]bydigestion,gelpurified,and insertedintoaBamHI/
EcoRI digest of pGEX-2T vector (Amersham Pharmacia), after
blunting the NcoI and BamHI sites of the insert and vector,
respectively. The NcoI and BamHI sites were blunted using the
Klenow fragment of Pol I (NEB).
pET-20b-YY1. For the construction of the YY1 bacterial
expression plasmid, the NcoI/EcoRI fragment of pGEX-2T-YY1,
described above, was subcloned into the multiple-cloning region of
pET-20b+ vector (Invitrogen, Carlsbad, CA). A sequence
encoding pelB leader secretion peptide is found upstream of the
multiple-cloning region. To remove this sequence, pET-20b+ was
digested with NdeI/NcoI, then blunted and religated. This
construct, once expressed in bacterial cells would produce non-
tagged YY1 protein.
Bacterial expression and purification of YY1
GST-YY1. Rosetta (DE3) cells (Novagen) were transformed
with the pGEX-2T-YY1 construct and grown overnight in LB
Miller broth medium (EMD) with ampicillin (100 mg/ml final
concentration). The overnight culture was diluted 1:10 in the same
medium (with ampicillin) and grown to a density of 0.6 O.D. (about
1 hour), then induced with isopropyl b-D-1-thiogalactopyranoside
(IPTG-Sigma-Aldrich) at a final concentration of 0.5 mM for about
4 hours. Cells were pelleted by centrifugation and then resuspended
in lysis buffer (ice-cold phosphate-buffered saline (PBS) pH 8.0 or
50 mM Tris pH 8.0, 150 mM NaCl) supplemented with a cocktail
of protease inhibitors (Sigma). The suspension was sonicated on ice
(three bursts, 15 seconds each, with 2 minutes intervals between
sonication bursts to allow cooling). Lysates were cleared by
centrifugation, then incubated with immobilized glutathione
beads (Pierce) with rocking for 2–4 hours at 4uC. The resulting
slurryofbeads and lysateswascentrifuged at5006g for2 minutes at
4uC. The beads were washed 3 times with lysis buffer. GST-YY1
was then eluted at 4uC from the beads with an equal volume of
50 mM Tris pH 8.0 containing 15 mM reduced glutathione
(Sigma). GST-YY1 protein was aliquoted and stored at 280uC
until used.
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were identical to those described above for the pGEX-2T-YY1
plasmid. However, after pelleting the Rosetta cells, the cells were
resuspended in denaturing buffer (8 M Urea, 100 mM NaH2PO4,
10 mM Tris, pH 8.0), and allowed to lyse, rocking for 45 minutes
at room temperature (RT). Lysates were cleared by centrifugation
at 180006g, at RT for 30 minutes. Nickel-nitrilotriacetic (Ni-
NTA) beads (Pierce), prewashed 3 times with 10 volumes each
time with lysis buffer, were added to the cleared lysates and rocked
for 1 hour at RT. The slurry of beads and lysates was then poured
into a column, and the beads were allowed to settle. Lysates were
drained by gravity. Ni-NTA beads were then washed one time
with 10 volumes of lysis buffer pH 8.0, followed by 3 washes with
lysis buffer pH 6.3. YY1 protein was eluted from the column with
lysis buffer pH 4.5, after first lowering the pH to 5.9. After analysis
of samples from the elution fractions on a 10% SDS-PAGE gel, by
Coomassie blue staining, YY1-containing fractions were pooled
and dialyzed to renature the protein. Renaturation was performed
by dialysis against 50 mM Tris pH 7.4, 150 mM NaCl, 1 mM
ZnSO4,5 m Mb-Mercaptoethanol, 1 M urea, for 2 hours.
Another dialysis step followed using the same buffer except that
the urea concentration was lowered to 0.1 M. Two additional
dialysis steps were performed in buffer lacking urea and b-
mercaptoethanol, for 2 hours each time. Dialysis in this solution
was repeated one more time overnight at 4uC. The renatured YY1
protein was aliquoted and stored at 280uC for later use.
Mutagenesis
Generation of YY1 point mutations at threonine 39 to alanine
was performed using pET-20b(+)-YY1 plasmid and then sub-
cloned into pGEX-2T-YY1. Mutagenesis was performed using
QuikChange II Site-Directed Mutagenesis Kit (Stratagene, La
Jolla, CA), according to the manufacturer’s instructions. The
threonine to alanine mutation was confirmed by sequencing. The






In vitro kinase assays
Kinase reactions were performed in kinase buffer (50 mM Tris
pH 7.4, 10 mM MgCl2,5 0mM ATP, 0.25 mM
32P-c-ATP, 5 mM
beta-glycerophosphate, 10 mM NaF, 1 mM DTT) for 30 minutes
at 30uC, with shaking. Purified Polo-like kinase 1 (Plk1) was
purchased from SignalChem (British Columbia, Canada). Reac-
tions were then stopped by the addition of SDS-PAGE buffer and
loaded for separation on a 10% SDS-PAGE gel. After staining
with Coomassie Brilliant Blue R-250, to visualize the protein
bands, gels were dried and exposed overnight to a Phosphor-
imager screen at room temperature. The screen was then scanned
on a Typhoon 9410 imager (GE Healthcare, Waukesha, WI) for
analysis.
For the cold kinase assays, no radioactive ATP was added, and
the cold ATP concentration was raised to 2 mM. After separation
on the SDS-PAGE gel, proteins were transferred to a nitrocellu-
lose membrane and probed with the indicated antibodies.
For the kinase assays using HeLa whole cell extracts as the
kinase source, extracts were added to GST-YY1 attached to
glutathione beads in kinase buffer. After incubation, the beads-
GST-YY1 complexes were pelleted by centrifugation, and cell
extracts we aspirated. Beads were washed 26with kinase buffer,
and then boiled in 26SDS-PAGE loading buffer, prior to loading
on the gel and subsequent Western blotting.
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